Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency)

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2018 $ 36 $ 2,717,538 $ (4,270,544) $ (1,552,970)
Balance at the beginning (in shares) at Dec. 31, 2018 3,599,300      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   5,502   5,502
Net loss     (464,944) (464,944)
Balance at the end at Mar. 31, 2019 $ 36 2,723,040 (4,735,488) (2,012,412)
Balance at the end (in shares) at Mar. 31, 2019 3,599,300      
Balance at the beginning at Dec. 31, 2018 $ 36 2,717,538 (4,270,544) (1,552,970)
Balance at the beginning (in shares) at Dec. 31, 2018 3,599,300      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of investor and placement agent warrants in connection with issuance of convertible notes payable, net of issuance costs       2,874,870
Stock-based compensation: Common stock       30,800
Net loss       (2,955,030)
Balance at the end at Sep. 30, 2019 $ 36 4,589,616 (7,225,574) (2,635,922)
Balance at the end (in shares) at Sep. 30, 2019 3,601,523      
Balance at the beginning at Mar. 31, 2019 $ 36 2,723,040 (4,735,488) (2,012,412)
Balance at the beginning (in shares) at Mar. 31, 2019 3,599,300      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of investor and placement agent warrants in connection with issuance of convertible notes payable, net of issuance costs [1]   437,901   437,901
Stock-based compensation: Options   5,258   5,258
Net loss     (1,135,178) (1,135,178)
Balance at the end at Jun. 30, 2019 $ 36 3,166,199 (5,870,666) (2,704,431)
Balance at the end (in shares) at Jun. 30, 2019 3,599,300      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of investor and placement agent warrants in connection with issuance of convertible notes payable, net of issuance costs [2]   1,387,483   1,387,483
Stock-based compensation: Options   5,134   5,134
Stock-based compensation: Common stock   30,800   30,800
Stock-based compensation: Common stock (in shares) 2,223      
Net loss     (1,354,908) (1,354,908)
Balance at the end at Sep. 30, 2019 $ 36 4,589,616 (7,225,574) (2,635,922)
Balance at the end (in shares) at Sep. 30, 2019 3,601,523      
Balance at the beginning at Dec. 31, 2019 $ 36 3,362,724 (8,403,417) (5,040,657)
Balance at the beginning (in shares) at Dec. 31, 2019 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   5,394   5,394
Net loss     (58,098) (58,098)
Balance at the end at Mar. 31, 2020 $ 36 3,368,118 (8,461,515) (5,093,361)
Balance at the end (in shares) at Mar. 31, 2020 3,601,521      
Balance at the beginning at Dec. 31, 2019 $ 36 3,362,724 (8,403,417) (5,040,657)
Balance at the beginning (in shares) at Dec. 31, 2019 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Common stock       12,000
Net loss       (5,727,918)
Balance at the end at Sep. 30, 2020 $ 77 21,723,133 (14,131,335) 7,591,875
Balance at the end (in shares) at Sep. 30, 2020 7,661,300      
Balance at the beginning at Mar. 31, 2020 $ 36 3,368,118 (8,461,515) (5,093,361)
Balance at the beginning (in shares) at Mar. 31, 2020 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   5,423   5,423
Stock-based compensation: Common stock   3,000   3,000
Stock-based compensation: Common stock (in shares) 1,112      
Forgiveness of accrued expenses by related party   33,738   33,738
Net loss     (1,505,320) (1,505,320)
Balance at the end at Jun. 30, 2020 $ 36 3,410,279 (9,966,835) (6,556,520)
Balance at the end (in shares) at Jun. 30, 2020 3,602,633      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock and warrants in initial public offering, net of issuance costs [3] $ 25 10,605,720   10,605,745
Issuance of common stock and warrants in initial public offering, net of issuance costs (in shares) [3] 2,500,000      
Conversion of notes payable and accrued interest into common stock and warrants $ 15 7,304,815   7,304,830
Conversion of notes payable and accrued interest into common stock and warrants (in shares) 1,461,090      
Conversion of notes payable and accrued interest into common stock $ 1 388,143   388,144
Conversion of notes payable and accrued interest into common stock (in shares) 94,223      
Stock-based compensation: Options   5,176   5,176
Stock-based compensation: Common stock   9,000   9,000
Stock-based compensation: Common stock (in shares) 3,334      
Effect of reverse stock split (in shares) 20      
Net loss     (4,164,500) (4,164,500)
Balance at the end at Sep. 30, 2020 $ 77 $ 21,723,133 $ (14,131,335) $ 7,591,875
Balance at the end (in shares) at Sep. 30, 2020 7,661,300      
[1] Net of issuance costs of $78,766
[2] Net of issuance costs of $970,720.
[3] Includes gross proceeds of $12,503,750, less issuance costs of $1,898,005.